Lupin Manufacturing Solutions Expands Dabhasa Facility to Scale Peptide and ADC Manufacturing Capabilities
核心洞察
Lupin Manufacturing Solutions (搜索) announced a strategic expansion of its Dabhasa manufacturing facility in India to enhance peptide building-blocks platform and CRDMO capabilities.
The expansion includes a new block with dedicated peptide manufacturing capacity across two additional specialized units to support complex therapeutics development.
The facility upgrades will enable advanced development and flexible manufacturing to meet global demand for complex pharmaceutical solutions including peptides (搜索) and biologic ADCs (搜索).
Lupin Manufacturing Solutions (搜索) (LMS), a global contract research, development and manufacturing organization (CRDMO) and subsidiary of Lupin Limited, announced a strategic expansion of its Dabhasa manufacturing facility in India, marking a significant step toward scaling its peptide building-blocks platform and CRDMO capabilities.
Facility Expansion Details
The expanded infrastructure features a new block designed to enhance existing CRDMO capabilities, supported by dedicated peptide manufacturing capacity across two additional specialized units. These upgrades will enable advanced development and flexible manufacturing, supporting complex therapeutics and meeting global demand for advanced pharmaceutical solutions.
Dr. Abdelaziz Toumi, Chief Executive Officer of Lupin Manufacturing Solutions (搜索), emphasized the strategic importance of the expansion: "As pharmaceutical innovation increasingly shifts toward complex modalities, building deep capabilities and execution excellence has become critical. This expansion underscores our commitment to building advanced, scalable capabilities that support complex development programs and reinforce our role in the global peptide ecosystem, enabling meaningful partnerships with innovators worldwide."
Addressing Complex Drug Development Needs
With global drug development increasingly defined by molecular complexity, such as peptides (搜索) and biologic antibody-drug conjugates (搜索) (ADCs (搜索)), this expansion reinforces LMS's capability to consistently supply high-quality peptide building blocks, including protected amino acids (搜索). The facility enhancement positions the company to better serve the growing demand for complex pharmaceutical manufacturing solutions.
Company Background
Lupin Manufacturing Solutions (搜索) Limited, a wholly owned subsidiary of Lupin Limited, operates as a leading manufacturer of Active Pharmaceutical Ingredients (APIs) and a global Contract Development and Manufacturing Organization (CDMO). The company offers standalone and integrated solutions across drug substances, complex chemistry, drug product, and advanced modalities, including ADCs (搜索) and peptides (搜索).
Leveraging Lupin's legacy of scientific rigor and regulatory expertise, LMS supports biopharma innovators from early development to commercial scale. The organization operates with state-of-the-art facilities, maintains a client-first approach, and employs a team of over 250 scientists to accelerate the path to market for transformative therapies.
Lupin Limited, the parent company, is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. The company specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients, maintaining 15 state-of-the-art manufacturing sites and 7 research centers globally with a workforce of over 24,000 professionals.